Study Details
Testing the Drug ONC201 for Pediatric Patients with Diffuse Midline Gliomas
(IRB#: IRB_00149140)
Diffuse Midline Gliomas is a fast-growing pediatric cancer that forms in the brain. This study will test a drug called ONC201, alone or in combination with other drugs or radiation, to treat the disease. This study wants to see if the drug will help people with the disease and is safe. Participants will receive either ONC201 only or ONC201 in combination with another drug or radiation. Study participation includes about 2 years of treatment and 5 years of follow-up. Medical tests and surveys will be done to track the health of participants.
- All genders
- All Ages
- Volunteers with special conditions
- In Person
- Unpaid
Who can participate?
Gender: All genders
Age: All Ages
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Age 2 to 39 years
- Diagnosed with Diffuse Midline Gliomas
- Must have adequate organ function of the body
- Must have recovered from all acute side effects of prior therapy and be beyond the window for expected ongoing acute toxicities
- Attend in person visit at the study clinic
Exclusion Criteria
- Diagnosis of a histone H3 wildtype Grade 2 diffuse astrocytoma
- Currently receiving other anti-cancer agents
- Currently receiving another investigational drug
- Known disorder that affects the immune system, such as HIV or Hepatitis B, or C, or an auto-immune disorder requiring systemic cytotoxic or immunosuppressive therapy
- Current uncontrolled infection or other uncontrolled systemic illness
Will I be paid for my time?
No
IRB#: IRB_00149140
PI: Nicholas Whipple
Department: PEDIATRIC HEMATOLOGY/ONCOLOGY
Approval Date: 2022-08-03 15:12:00
Study Categories: Cancer Studies
Specialties: Pediatric Hematology & Oncology
I am Interested